Bavarian Nordic to Raise $250 Million for RSV Vaccine Phase 3 Trial
(PLX AI) - Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base.• Says total estimated cost of the study is approximately USD 250 million,
Source: finanznachrichten.de